Results 61 to 70 of about 5,730 (206)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

Virology Journal, 2018
Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.
Fabien Zoulim, Christophe Moreno, Samuel S. Lee, Peter Buggisch, Andrzej Horban, Eric Lawitz, Chris Corbett, Oliver Lenz, Bart Fevery, Thierry Verbinnen, Umesh Shukla, Wolfgang Jessner   +11 more
doaj   +1 more source

A prospective study in hepatitis C virus treatment-naïve patients showing rheumatologic extra-hepatic manifestations of hepatitis C with associated risk factors: efficacy and safety using sofosbuvir-based direct antiviral therapy

Egyptian Rheumatology and Rehabilitation, 2020
Background To study the most common rheumatologic manifestations of hepatitis C viral (HCV) infection in Egyptian patients and associated risk factors with assessment the effect of current therapies on these manifestations.
Hanan M. Fathi, Wafaa Y. Abdel Wahed, Ahmad A. Gomaa, Essam A. Hassan, Hanaa M. Eid, Fadwa Abdel Reheem, Soha H. Senara   +6 more
doaj   +1 more source

Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT Chronic hepatitis C virus (HCV) infection can be associated with neuropsychiatric symptoms like fatigue and cognitive impairment, independent of the liver status. The present study aims to assess changes in the pattern and extent of neuropsychological symptoms after successful treatment with interferon (IFN)‐based and IFN‐free therapy.
Meike Dirks, Ann‐Katrin Hennemann, Gerrit M. Grosse, Anika Beer, Henning Pflugrad, Kim Haag, Ramona Schuppner, Katja Deterding, Markus Cornberg, Heiner Wedemeyer, Karin Weissenborn   +10 more
wiley   +1 more source

Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy [PDF]

, 2014
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors.
Carpio Pedroza, Juan Carlos, Cruz Rivera, Mayra, Escobar Gutierrez, Alejandro, Fonseca Coronado, Salvador, Martinez Guarneros, Armando, Preciado, María Victoria, Rahal, Paula, Ruiz Tovar, Karina, Valva, Pamela, Vazquez Chacon, Carlos, Yamasaki, Lilian   +10 more
core   +1 more source

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions

MedComm, Volume 6, Issue 3, March 2025.
The malignant transformation from chronic viral hepatitis to hepatocellular carcinoma (HCC) involves intricate interactions among viral, host, and environmental factors. Key drivers of this transformation include viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune ...
Huimin Yuan, Ruochen Xu, Senlin Li, Mengzhu Zheng, Qingyi Tong, Ming Xiang, Yonghui Zhang   +6 more
wiley   +1 more source

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

Brazilian Journal of Nephrology, 2020
In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with
Raissa M Arruda, Andrea D Batista, Norma A Filgueira, Izolda F Moura, Luis H Sette, Edmundo P Lopes   +5 more
doaj   +2 more sources

HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil [PDF]

, 2014
Background: Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million people worldwide. the aim of this study is to analyze the subtypes and existence of variants resistant to protease inhibitors and their ...
Alencar, Cecilia S., Almeida-Neto, Cesar de, Di-Lorenzo-Oliveira, Claudia, Ferreira, Suzete C., Levi, Jose E., Mendrone, Alfredo, Nishiya, Anna S., Sabino, Ester Cerdeira, Salles, Nanci A.   +8 more
core   +3 more sources

Alphavirus nsP2: A Multifunctional Regulator of Viral Replication and Promising Target for Anti‐Alphavirus Therapies

Reviews in Medical Virology, Volume 35, Issue 2, March 2025.
ABSTRACT Alphaviruses are re‐emerging vector‐born pathogens that cause arthralgia or encephalitic diseases on a global scale. While a vaccine against chikungunya virus was recently approved, no vaccines currently exist for other alphaviruses, nor are there antiviral drugs for the treatment of alphavirus infections. Alphaviruses have positive‐strand RNA
Sainan Wang, Suresh Mahalingam, Andres Merits   +2 more
wiley   +1 more source

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease

Журнал инфектологии, 2016
The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and ...
A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin   +4 more
doaj  

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. [PDF]

, 2018
AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe ...
Aby, Elizabeth S, Benhammou, Jihane N, Dong, Tien S, Han, Steven-Huy, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +6 more
core